Ireland
--:--IST
Recruiting Not applicable

Different Hemostatic Agents Used in Partial Pulpotomy on Pulp Survival and Postoperative Pain

NCT07058727 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-05-01
Last updated
2026-04-01

Condition(s) studied

Efficacy of Hemostatic AgentsPartial PulpotomyPostoperative Pain

Investigational drug(s) / intervention(s)

Sodium Hypochlorite 2,5% →Chlorhexidine →Cold Saline

Sodium Hypochlorite 2,5%: 2.5% NaOCl applied for 1 min to exposed pulp for hemostasis, followed by standard pulp capping

Chlorhexidine: 2% CHX applied for 1 min to achieve hemostasis, with identical subsequent steps to NaOCl group

Cold Saline: Hemostasis via 4°C saline (1 Min), then standardized pulp capping

Study summary

This randomized clinical trial evaluates the efficacy of sodium hypochlorite (NaOCl), chlorhexidine (CHX), and cold saline as hemostatic agents in partial pulpotomy. The study compares postoperative pain (via VAS scores) and pulp survival (via clinical/radiographic evaluation) at 1, 3, 7 days, 6 months, and 12 months

Eligibility

Sex
ALL
Min age
15 Years
Max age
55 Years
Healthy volunteers
No
Inclusion Criteria: * Permanent teeth with carious pulp exposure (no spontaneous pain). * Positive vitality test (Endo-Ice). * No periapical radiolucency. Exclusion Criteria: * Systemic diseases affecting healing. * Pregnancy. * Non-vital pulp/necrosis

Primary outcome measure(s)

  • Postoperative Pain — 1 week
    The patient will be asked to rate the pain on the 1st, 3rd and 7th day according to VAS. (The patient is asked to score their pain in this range, with 0 being the lowest and 10 being the highest.)
  • Pulp Survival Rate — 12 months
    The pulp is expected to be vital, without percussion tenderness and without spontaneous pain

Trial sites (1)

FacilityCityRegionStatus
Çukurova Üniversitesi Diş Hekimliği Fakültesi Adana Sarıçam Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07058727 on ClinicalTrials.gov ↗ ← All trials in Turkey